Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 21 Results

Title
Intervention Indication Therapeutic Area Year Actions
Benralizumab for treating eosinophilic oesophagitis in people aged 12-65 years Benralizumab (Fasenra; MEDI563) Eosinophilic oesophagitis Gastroenterology 2022 View  |  Download
Budesonide for Ulcerative Proctitis Budesonide gastro-resistant (Budenofalk) Ulcerative proctitis Gastroenterology 2021 View  |  Download
Budesonide granules for induction of remission in lymphocytic colitis – first line Budesonide gastro-resistant (Budenofalk) Lymphocytic colitis Gastroenterology , Immunology 2020 View  |  Download
Dupilumab for treating eosinophilic oesophagitis in people aged 12 years and older Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893) Eosinophilic oesophagitis Gastroenterology , Immunology 2022 View  |  Download
Eflornithine in combination with Sulindac for Familial Adenomatus Polyposis Eflornithine (CPP-1X; Difluoromethylornithine; DFMO; Vaniqa; eflornithine hydrochloride monohydrate) , Sulindac Familial adenomatous polyposis (FAP) Gastroenterology , Genetic Disorders 2018 View  |  Download
Etrasimod for treating moderately to severely active ulcerative colitis Etrasimod (ADP334) Ulcerative colitis Gastroenterology 2022 View  |  Download
Etrolizumab for Crohn’s Disease Etrolizumab (PRO145223; RG7413; rhuMAb Beta7) Crohn's disease Gastroenterology , Immunology 2021 View  |  Download
Etrolizumab for treating moderately to severely active ulcerative colitis in adults Etrolizumab (PRO145223; RG7413; rhuMAb Beta7) Ulcerative colitis Gastroenterology 2020 View  |  Download
Filgotinib for moderately to severely active ulcerative colitis Filgotinib (GLPG-0634; filgotinib maleate) Ulcerative colitis Gastroenterology 2019 View  |  Download
Mirikizumab for the treatment of moderately to severely active ulcerative colitis Mirikizumab (LY3074828) Ulcerative colitis Gastroenterology 2021 View  |  Download
1 2 3
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications